Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound
Michael J Corley, Alina P S Pang, Thomas A Rasmussen, Martin Tolstrup, Ole S Søgaard, Lishomwa C Ndhlovu, Michael J Corley, Alina P S Pang, Thomas A Rasmussen, Martin Tolstrup, Ole S Søgaard, Lishomwa C Ndhlovu
Abstract
Objective: This study aimed to identify candidate host epigenetic biomarkers predicting latency reversal agents (LRA) efficacy and HIV-1 rebound kinetics during analytical treatment interruption (ATI).
Design: Retrospective longitudinal epigenetic profiling study from 13 people with HIV (PWH) on virologically suppressive antiretroviral therapy (ART) that participated in a LRA (HDAC inhibitor) clinical trial (NCT01680094) and a subsequent optional ATI to monitor for viral recrudescence after ART cessation.
Methods: Genome-wide DNA methylation (DNAm) in purified CD4+ T cells was measured at single-nucleotide resolution using the Infinium MethylationEPIC array. HIV-1 DNA and RNA measures were previously assessed by PCR-based methods and the association of DNAm levels at regulatory sites of the human genome were examined with reservoir size, responsiveness to LRA, and time to viral rebound following ATI.
Results: A distinct set of 15 candidate DNAm sites in purified CD4+ T cells at baseline pre-LRA and pre-ATI significantly correlated with time to viral rebound. Eight of these DNAm sites occurred in genes linked to HIV-1 replication dynamics including (SEPSECS, cg19113954), (MALT1, cg15968021), (CPT1C, cg14318858), (CRTAM, cg10977115), (B4GALNT4, cg04663285), (IL10, cg16284789), (TFPI2, cg19645693), and (LIFR, cg26437306); with the remaining sites at intergenic regions containing regulatory elements. Moreover, baseline DNAm states related to total HIV-1 DNA levels and the fold change in unspliced cell-associated HIV RNA following LRA treatment.
Conclusion: Preexisting host epigenetic states may determine HIV-1 rebound kinetics and reservoir maintenance. These findings suggest integrating a suite of DNA methylation markers to improve optimal participant selection and drug regimen in future HIV cure clinical trials.
Conflict of interest statement
CONFLICT OF INTEREST
LCN has served as a scientific advisor for Abbvie, ViiV and Cytodyn for work unrelated to this project. OSS has served as a scientific advisor for Abbvie, Gilead, Mologen AG, and Immunocore for work unrelated to this project. All other authors declare no competing interests.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Figures
![Figure 1:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8563431/bin/nihms-1737743-f0001.jpg)
![Figure 2:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8563431/bin/nihms-1737743-f0002.jpg)
Figure 3:
DNA methylation sites associated with…
Figure 3:
DNA methylation sites associated with cell associated unspliced HIV-1 increase following LRA and…
Figure 4:
Venn diagram of overlap between…
Figure 4:
Venn diagram of overlap between differentially methylated loci comparing baseline, early Panobinostat treatment,…
Figure 5:
Differentially methylated loci impacted by…
Figure 5:
Differentially methylated loci impacted by early and late Panobinostat treatment in CD4+ T…
- Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.Giron LB, Papasavvas E, Yin X, Goldman AR, Tang HY, Palmer CS, Landay AL, Li JZ, Koethe JR, Mounzer K, Kostman JR, Liu Q, Montaner LJ, Abdel-Mohsen M. Giron LB, et al. mBio. 2021 Feb 23;12(1):e03444-20. doi: 10.1128/mBio.03444-20. mBio. 2021. PMID: 33622719 Free PMC article.
- Abstracts of Presentations at the Association of Clinical Scientists 143rd Meeting Louisville, KY May 11-14,2022.[No authors listed] [No authors listed] Ann Clin Lab Sci. 2022 May;52(3):511-525. Ann Clin Lab Sci. 2022. PMID: 35777803 No abstract available.
- Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model.Goswami R, Nelson AN, Tu JJ, Dennis M, Feng L, Kumar A, Mangold J, Mangan RJ, Mattingly C, Curtis AD 2nd, Obregon-Perko V, Mavigner M, Pollara J, Shaw GM, Bar KJ, Chahroudi A, De Paris K, Chan C, Van Rompay KKA, Permar SR. Goswami R, et al. mBio. 2019 Sep 5;10(5):e01971-19. doi: 10.1128/mBio.01971-19. mBio. 2019. PMID: 31488511 Free PMC article.
- Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.Oriol-Tordera B, Esteve-Codina A, Berdasco M, Rosás-Umbert M, Gonçalves E, Duran-Castells C, Català-Moll F, Llano A, Cedeño S, Puertas MC, Tolstrup M, Søgaard OS, Clotet B, Martínez-Picado J, Hanke T, Combadiere B, Paredes R, Hartigan-O'Connor D, Esteller M, Meulbroek M, Calle ML, Sanchez-Pla A, Moltó J, Mothe B, Brander C, Ruiz-Riol M. Oriol-Tordera B, et al. EBioMedicine. 2022 Apr;78:103956. doi: 10.1016/j.ebiom.2022.103956. Epub 2022 Mar 21. EBioMedicine. 2022. PMID: 35325780 Free PMC article.
- Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption.Prator CA, Thanh C, Kumar S, Pan T, Peluso MJ, Bosch R, Jones N, Milush JM, Bakkour S, Stone M, Busch MP, Deeks SG, Hunt PW, Henrich TJ. Prator CA, et al. J Infect Dis. 2020 Mar 16;221(7):1146-1155. doi: 10.1093/infdis/jiz572. J Infect Dis. 2020. PMID: 31677350 Free PMC article.
- Cellular resistance to an oncolytic virus is driven by chronic activation of innate immunity.Larrieux A, Sanjuán R. Larrieux A, et al. iScience. 2022 Dec 7;26(1):105749. doi: 10.1016/j.isci.2022.105749. eCollection 2023 Jan 20. iScience. 2022. PMID: 36590165 Free PMC article.
- Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.Giron LB, Abdel-Mohsen M. Giron LB, et al. Curr HIV/AIDS Rep. 2022 Jun;19(3):217-233. doi: 10.1007/s11904-022-00607-z. Epub 2022 Apr 19. Curr HIV/AIDS Rep. 2022. PMID: 35438384 Review.
- Research Support, N.I.H., Extramural
- Anti-Retroviral Agents / therapeutic use
- CD4-Positive T-Lymphocytes
- Epigenesis, Genetic
- HIV Infections* / drug therapy
- HIV-1* / genetics
- Humans
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Viral Load
- Virus Latency
- Anti-Retroviral Agents
- ClinicalTrials.gov/NCT01680094
- Full Text Sources
- Medical
- Research Materials
- Miscellaneous
![Figure 3:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8563431/bin/nihms-1737743-f0003.jpg)
![Figure 4:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8563431/bin/nihms-1737743-f0004.jpg)
![Figure 5:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8563431/bin/nihms-1737743-f0005.jpg)
Source: PubMed